Clinical Trial

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-22.
Trial Details
NCT Number NCT06948981
Lead Sponsor Grit Biotechnology
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions Hematological Malignancy (Leukemia- Lymphoma)
Enrollment 46 participants
Start Date 2025-04-18
Primary Completion 2028-04-17 (estimated)
Study Completion 2028-04-17 (estimated)
Updated on ClinicalTrials.gov 2025-09-16